October 28th 2024
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Study Looks for Ways to Reduce Incidence of Tobacco-Associated Pancreatic Cancer
November 17th 2022In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.
Read More
Escalating Radiation Dose Shows Promise in Patients With Locally Advanced Pancreatic Cancer
November 17th 2022In an interview with Targeted Oncology, Michael Chuong, MD, discussed how 5 fractions of ablative radiation therapy compare with 15-25 fractions for the treatment of locally advanced pancreatic cancer.
Read More
Phase 3 FRUTIGA Study of Fruquintinib Elicits Positive Results in Gastric/GEJ Cancers
November 16th 2022Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
GOBLET Trial’s Pancreatic Cohort Displays High Efficacy With Pelareorep/Atezolizumab
November 8th 2022Treatment with pelareorep plus atezolizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma led to an overall response rate nearly triple than the average which were previously reported in historical control trials.
Read More
Health Derailed in Houston After Authorities Confirm Liver Cancer Cluster
October 31st 2022Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.
Read More
DeFianCe Study of DKN-01/Bevacizumab/Chemo Enrolls First Patient With Colorectal Cancer
October 19th 2022The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.
Read More
Study of Onvansertib Plus SOC in Metastatic Colorectal Cancer Enters Phase 2
September 19th 2022Following reports of durable response in a phase 1 study, the combination of onvansertib FOLFIRI, and bevacizumab will be evaluating in a phase 2 study of patients with metastatic colorectal cancer.
Read More
RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma
September 11th 2022A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.
Read More
ISGIO® Seeks to Clarify Gastrointestinal Cancer Updates for the Clinic
August 31st 2022During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.
Read More
Durvalumab Triplet Improves OS Across Biliary Tract Cancer Locations
August 23rd 2022In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.
Read More
Frontline Therapy Shows 3-Fold OS Improvement vs BSC in Unresectable Advanced or Metastastic ESCC
August 11th 2022Earlier treatment in patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma may offer better survival benefit compared with chemotherapy or best supportive care.
Read More